140 related articles for article (PubMed ID: 28390192)
1. Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.
Kaptan E; Sancar Bas S; Sancakli A; Aktas HG; Bayrak BB; Yanardag R; Bolkent S
J Cell Biochem; 2017 Nov; 118(11):3911-3919. PubMed ID: 28390192
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas.
Niu DF; Kondo T; Nakazawa T; Oishi N; Kawasaki T; Mochizuki K; Yamane T; Katoh R
Lab Invest; 2012 Aug; 92(8):1181-90. PubMed ID: 22641097
[TBL] [Abstract][Full Text] [Related]
3. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells.
Endo T; Ohta K; Kobayashi T
J Clin Endocrinol Metab; 2008 Jun; 93(6):2409-12. PubMed ID: 18381576
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
Arcolia V; Journe F; Wattier A; Leteurtre E; Renaud F; Gabius HJ; Remmelink M; Decaestecker C; Rodriguez A; Boutry S; Laurent S; Saussez S
Int J Oncol; 2017 Sep; 51(3):760-770. PubMed ID: 28677745
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
6. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression.
Salajegheh A; Dolan-Evans E; Sullivan E; Irani S; Rahman MA; Vosgha H; Gopalan V; Smith RA; Lam AK
Exp Mol Pathol; 2014 Apr; 96(2):212-8. PubMed ID: 24530443
[TBL] [Abstract][Full Text] [Related]
7. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
8. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
9. Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.
Ghoneim C; Soula-Rothhut M; Blanchevoye C; Martiny L; Antonicelli F; Rothhut B
J Biol Chem; 2007 May; 282(21):15490-7. PubMed ID: 17409099
[TBL] [Abstract][Full Text] [Related]
10. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer.
Dalle Carbonare L; Frigo A; Francia G; Davì MV; Donatelli L; Stranieri C; Brazzarola P; Zatelli MC; Menestrina F; Valenti MT
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1249-56. PubMed ID: 22511796
[TBL] [Abstract][Full Text] [Related]
11. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.
Carr FE; Tai PW; Barnum MS; Gillis NE; Evans KG; Taber TH; White JH; Tomczak JA; Jaworski DM; Zaidi SK; Lian JB; Stein JL; Stein GS
Endocrinology; 2016 Aug; 157(8):3278-92. PubMed ID: 27253998
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
13. Runx2 is expressed in human glioma cells and mediates the expression of galectin-3.
Vladimirova V; Waha A; Lückerath K; Pesheva P; Probstmeier R
J Neurosci Res; 2008 Aug; 86(11):2450-61. PubMed ID: 18438928
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of PIWIL2 in papillary thyroid cancers.
Erdogdu IH; Yumrutas O; Ozgur Cevik M; Bozgeyik I; Erdogdu M; Inan HM; Bagis H
Gene; 2018 Apr; 649():8-13. PubMed ID: 29369786
[TBL] [Abstract][Full Text] [Related]
15. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma].
López Mondéjar P; Picó A; Seguí J; López Maciá A
Med Clin (Barc); 2008 Feb; 130(5):161-4. PubMed ID: 18341829
[TBL] [Abstract][Full Text] [Related]
17. [Expression of TTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, galectin-3 and mucin-1 genes].
Chen Y; Zhu M; Zhou X; Lin W; Ni C; Li F; Zhang S; Gong Z
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):257-61. PubMed ID: 11953175
[TBL] [Abstract][Full Text] [Related]
18. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.
Zhao Z; Herman JG; Brock MV; Sheng J; Zhang M; Liu B; Guo M
PLoS One; 2014; 9(11):e112336. PubMed ID: 25375359
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
[TBL] [Abstract][Full Text] [Related]
20. Identification of targets of Twist1 transcription factor in thyroid cancer cells.
Di Maro G; Orlandella FM; Bencivenga TC; Salerno P; Ugolini C; Basolo F; Maestro R; Salvatore G
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1617-26. PubMed ID: 24848707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
